| Recruitment status | Open public recruiting |
| Unique ID issued by UMIN | UMIN000045402 |
| Receipt No. | R000051807 |
| Scientific Title | The effect of an environmental sound with inaudible high-frequency band on acute social stress responses: A psychophysiological examination |
| Date of disclosure of the study information | 2021/09/11 |
| Last modified on | 2021/09/07 (Ver. 1) |
| Basic information | ||
| Public title | The effect of an environmental sound with inaudible high-frequency band on acute social stress responses: A psychophysiological examination | |
| Acronym | The effect of an environmental sound with inaudible high-frequency band on acute social stress responses: A psychophysiological examination | |
| Scientific Title | The effect of an environmental sound with inaudible high-frequency band on acute social stress responses: A psychophysiological examination | |
| Scientific Title:Acronym | The effect of an environmental sound with inaudible high-frequency band on acute social stress responses: A psychophysiological examination | |
| Region |
|
|
| Condition | ||
| Condition | none | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | The purpose of this study is to determine whether an environmental sound with high frequency band improves tolerance and enhances efficiency of recovery from social stress that experimentally induced. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | State-Trait Anxiety Inventory
Stress level by visual analogue scale Heart rate(HR) Heart rate variability(HRV) Alpha-amylase in saliva |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Factorial |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | NO |
| Dynamic allocation | NO |
| Institution consideration | Institution is not considered as adjustment factor. |
| Blocking | NO |
| Concealment | Pseudo-randomization |
| Intervention | ||
| No. of arms | 3 | |
| Purpose of intervention | Educational,Counseling,Training | |
| Type of intervention |
|
|
| Interventions/Control_1 | playing an environmental sound with high frequency band. | |
| Interventions/Control_2 | playing an environmental sound without high frequency band. | |
| Interventions/Control_3 | playing no sound | |
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male | |||
| Key inclusion criteria | Those who reports intact auditory and visual acuity could participate in this study. They are all 20's males and female is not supposed to be included in this study because cortisol would vary with menstrual cycle and it is difficult to control it.
|
|||
| Key exclusion criteria | We set exclusion criteria as follows.
1. Those who would not follow our infection prevention. 2. Those who have been COVID positive or have COVID positive housemate within 2 weeks. 3. Those who go to the hospital or take medication for the purpose of treating illnesses and injuries other than allergies. 4. Those who have or have a history of mental illness or cranial nerve illness. 5. Those who have heart / circulatory system (myocardial infarction, angina, aortic aneurysm, etc.), hyperglycemia, hypertension (or similar, upper blood pressure is 140 mmHg or higher, lower blood pressure is 90 mmHg or higher) or have a history of those. 6. Those who have or have a history of respiratory system (asthma, etc.) 7. Those who have or have f a history of digestive system (hepatitis, etc.) 8. Those who have been pointed out to have depression, hypertension, hyperglycemia, or abnormal electrocardiogram in a medical examination or a hospital examination. 9. Those who smoke habitually. 10. Those who take drugs habitually. 11. Those who consume excessive alcohol. 12. Those who are taking excessive caffeine. 13. Those who are claustrophobic or who may experience strong anxiety or fear in tight or dark spaces. 14. Those who have bleeding wounds / inflammation, blisters, or blisters on the chest or abdomen. 15. Those who are excessively obese or lean. 16. Those with diabetes, coronary heart disease, cancer, or chronic obstructive pulmonary disease. 17. Those who have a profession that involves night shifts. 18. Those who are in poor health, those who are physically unhealthy. |
|||
| Target sample size | 66 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Centan Inc. | ||||||
| Division name | Research and Development | ||||||
| Zip code | 108-0075 | ||||||
| Address | 11F, Shinagawa East One Tower, 2-16-1, Konan, Minato city, Tokyo | ||||||
| TEL | 03-6670-6722 | ||||||
| moriya@centan.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Centan Inc. | ||||||
| Division name | Research and Development | ||||||
| Zip code | 108-0075 | ||||||
| Address | 11F, Shinagawa East One Tower, 2-16-1, Konan, Minato city, Tokyo | ||||||
| TEL | 03-6670-6722 | ||||||
| Homepage URL | |||||||
| moriya@centan.jp | |||||||
| Sponsor | |
| Institute | Centan Inc. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | MIRISE Technologies |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Public Health Research Foundation |
| Address | 1-1-7, Nishi-Waseda, Shinjyuku city, Tokyo |
| Tel | 03-5287-5070 |
| rinri@phrf.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Open public recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000051807 |